A vs. CRL: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at A and CRL, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | A | CRL |
|---|---|---|
| Company Name | Agilent Technologies, Inc. | Charles River Laboratories International, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 39.92 billion USD | 8.54 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | November 18, 1999 | June 23, 2000 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of A and CRL by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | A | CRL |
|---|---|---|
| 5-Day Price Return | 1.52% | -1.08% |
| 13-Week Price Return | 16.08% | 9.12% |
| 26-Week Price Return | 28.39% | 23.05% |
| 52-Week Price Return | -2.14% | -8.32% |
| Month-to-Date Return | 9.71% | 10.87% |
| Year-to-Date Return | 4.82% | -6.03% |
| 10-Day Avg. Volume | 2.01M | 1.02M |
| 3-Month Avg. Volume | 1.76M | 0.90M |
| 3-Month Volatility | 34.01% | 46.61% |
| Beta | 1.27 | 1.63 |
Profitability
Return on Equity (TTM)
A
19.97%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.51%
- Median
- 6.47%
- Q1
- 3.86%
- Min
- -6.95%
A’s Return on Equity of 19.97% is exceptionally high, placing it well beyond the typical range for the Life Sciences Tools & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
CRL
-2.01%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.51%
- Median
- 6.47%
- Q1
- 3.86%
- Min
- -6.95%
CRL has a negative Return on Equity of -2.01%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
A
17.97%
Life Sciences Tools & Services Industry
- Max
- 32.18%
- Q3
- 18.30%
- Median
- 10.19%
- Q1
- 4.20%
- Min
- -2.05%
A’s Net Profit Margin of 17.97% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
CRL
-1.72%
Life Sciences Tools & Services Industry
- Max
- 32.18%
- Q3
- 18.30%
- Median
- 10.19%
- Q1
- 4.20%
- Min
- -2.05%
CRL has a negative Net Profit Margin of -1.72%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
A
21.26%
Life Sciences Tools & Services Industry
- Max
- 38.39%
- Q3
- 21.40%
- Median
- 13.57%
- Q1
- 8.38%
- Min
- -3.51%
A’s Operating Profit Margin of 21.26% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
CRL
3.09%
Life Sciences Tools & Services Industry
- Max
- 38.39%
- Q3
- 21.40%
- Median
- 13.57%
- Q1
- 8.38%
- Min
- -3.51%
CRL’s Operating Profit Margin of 3.09% is in the lower quartile for the Life Sciences Tools & Services industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
Profitability at a Glance
| Symbol | A | CRL |
|---|---|---|
| Return on Equity (TTM) | 19.97% | -2.01% |
| Return on Assets (TTM) | 10.14% | -0.90% |
| Net Profit Margin (TTM) | 17.97% | -1.72% |
| Operating Profit Margin (TTM) | 21.26% | 3.09% |
| Gross Profit Margin (TTM) | 52.92% | 35.03% |
Financial Strength
Current Ratio (MRQ)
A
2.25
Life Sciences Tools & Services Industry
- Max
- 3.46
- Q3
- 2.78
- Median
- 1.91
- Q1
- 1.53
- Min
- 0.43
A’s Current Ratio of 2.25 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
CRL
1.36
Life Sciences Tools & Services Industry
- Max
- 3.46
- Q3
- 2.78
- Median
- 1.91
- Q1
- 1.53
- Min
- 0.43
CRL’s Current Ratio of 1.36 falls into the lower quartile for the Life Sciences Tools & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
A
0.54
Life Sciences Tools & Services Industry
- Max
- 1.35
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
A’s Debt-to-Equity Ratio of 0.54 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
CRL
0.70
Life Sciences Tools & Services Industry
- Max
- 1.35
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
CRL’s Debt-to-Equity Ratio of 0.70 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
A
254.50
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
With an Interest Coverage Ratio of 254.50, A demonstrates a superior capacity to service its debt, placing it well above the typical range for the Life Sciences Tools & Services industry. This stems from either robust earnings or a conservative debt load.
CRL
1.71
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
In the lower quartile for the Life Sciences Tools & Services industry, CRL’s Interest Coverage Ratio of 1.71 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
Financial Strength at a Glance
| Symbol | A | CRL |
|---|---|---|
| Current Ratio (MRQ) | 2.25 | 1.36 |
| Quick Ratio (MRQ) | 1.71 | 0.96 |
| Debt-to-Equity Ratio (MRQ) | 0.54 | 0.70 |
| Interest Coverage Ratio (TTM) | 254.50 | 1.71 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
A
0.70%
Life Sciences Tools & Services Industry
- Max
- 1.41%
- Q3
- 0.65%
- Median
- 0.35%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 0.70%, A offers a more attractive income stream than most of its peers in the Life Sciences Tools & Services industry, signaling a strong commitment to shareholder returns.
CRL
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.41%
- Q3
- 0.65%
- Median
- 0.35%
- Q1
- 0.00%
- Min
- 0.00%
CRL currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
A
22.95%
Life Sciences Tools & Services Industry
- Max
- 113.14%
- Q3
- 61.34%
- Median
- 17.74%
- Q1
- 0.00%
- Min
- 0.00%
A’s Dividend Payout Ratio of 22.95% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
CRL
0.00%
Life Sciences Tools & Services Industry
- Max
- 113.14%
- Q3
- 61.34%
- Median
- 17.74%
- Q1
- 0.00%
- Min
- 0.00%
CRL has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | A | CRL |
|---|---|---|
| Dividend Yield (TTM) | 0.70% | 0.00% |
| Dividend Payout Ratio (TTM) | 22.95% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
A
32.99
Life Sciences Tools & Services Industry
- Max
- 75.35
- Q3
- 51.00
- Median
- 32.93
- Q1
- 25.27
- Min
- 1.43
A’s P/E Ratio of 32.99 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
CRL
--
Life Sciences Tools & Services Industry
- Max
- 75.35
- Q3
- 51.00
- Median
- 32.93
- Q1
- 25.27
- Min
- 1.43
P/E Ratio data for CRL is currently unavailable.
Price-to-Sales Ratio (TTM)
A
5.93
Life Sciences Tools & Services Industry
- Max
- 10.49
- Q3
- 6.43
- Median
- 4.66
- Q1
- 2.88
- Min
- 1.08
A’s P/S Ratio of 5.93 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
CRL
2.12
Life Sciences Tools & Services Industry
- Max
- 10.49
- Q3
- 6.43
- Median
- 4.66
- Q1
- 2.88
- Min
- 1.08
In the lower quartile for the Life Sciences Tools & Services industry, CRL’s P/S Ratio of 2.12 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
A
5.12
Life Sciences Tools & Services Industry
- Max
- 6.69
- Q3
- 5.00
- Median
- 3.46
- Q1
- 2.38
- Min
- 0.93
A’s P/B Ratio of 5.12 is in the upper tier for the Life Sciences Tools & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
CRL
2.22
Life Sciences Tools & Services Industry
- Max
- 6.69
- Q3
- 5.00
- Median
- 3.46
- Q1
- 2.38
- Min
- 0.93
CRL’s P/B Ratio of 2.22 is in the lower quartile for the Life Sciences Tools & Services industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | A | CRL |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 32.99 | -- |
| Price-to-Sales Ratio (TTM) | 5.93 | 2.12 |
| Price-to-Book Ratio (MRQ) | 5.12 | 2.22 |
| Price-to-Free Cash Flow Ratio (TTM) | 36.99 | 14.76 |